ZNF100

Summary

ZNF100 (zinc finger protein 100, HGNC:12880) is a protein-coding gene on chromosome 19p13.1, encoding Zinc finger protein 100 (Q8IYN0). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of DNA-templated transcription. Predicted to be located in nucleus.

Source: NCBI Gene 163227 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 124 total
• MANE Select transcript: NM_173531

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12880
Approved symbol	ZNF100
Name	zinc finger protein 100
Location	19p13.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000197020
Ensembl biotype	protein_coding
OMIM	603982
Entrez	163227

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000305570, ENST00000358296, ENST00000594401, ENST00000596452, ENST00000598026, ENST00000897459, ENST00000925419

RefSeq mRNA: 5 — MANE Select: NM_173531 NM_001351669, NM_001351670, NM_001351671, NM_001351672, NM_173531

CCDS: CCDS42538

Canonical transcript exons

ENST00000358296 — 5 exons

Exon	Start	End
ENSE00001527418	21722771	21727989
ENSE00001611399	21744017	21744115
ENSE00001630371	21765694	21765786
ENSE00003557069	21744941	21745067
ENSE00003846960	21767427	21767579

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 82.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.1793 / max 237.4867, expressed in 1654 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180233	10.2257	1633
180232	1.9536	817

Top tissues by expression

137 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus callosum	UBERON:0002336	82.53	gold quality
calcaneal tendon	UBERON:0003701	81.57	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.94	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.94	gold quality
ganglionic eminence	UBERON:0004023	79.91	gold quality
endometrium	UBERON:0001295	79.78	gold quality
bone marrow cell	CL:0002092	79.38	gold quality
colonic epithelium	UBERON:0000397	79.21	gold quality
ventricular zone	UBERON:0003053	79.19	gold quality
adrenal tissue	UBERON:0018303	78.80	gold quality
bone marrow	UBERON:0002371	78.49	gold quality
tonsil	UBERON:0002372	78.46	gold quality
monocyte	CL:0000576	78.36	gold quality
leukocyte	CL:0000738	78.29	gold quality
islet of Langerhans	UBERON:0000006	76.13	gold quality
lymph node	UBERON:0000029	76.07	gold quality
testis	UBERON:0000473	75.54	gold quality
skeletal muscle tissue	UBERON:0001134	75.06	gold quality
left testis	UBERON:0004533	75.05	gold quality
right testis	UBERON:0004534	74.74	gold quality
vermiform appendix	UBERON:0001154	74.40	gold quality
muscle tissue	UBERON:0002385	74.29	gold quality
sural nerve	UBERON:0015488	74.17	gold quality
rectum	UBERON:0001052	73.87	gold quality
smooth muscle tissue	UBERON:0001135	73.24	gold quality
placenta	UBERON:0001987	73.17	gold quality
pancreas	UBERON:0001264	73.08	gold quality
stromal cell of endometrium	CL:0002255	73.07	gold quality
right adrenal gland cortex	UBERON:0035827	72.93	gold quality
adrenal gland	UBERON:0002369	72.84	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

121 targeting ZNF100, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-590-3P	99.96	74.34	6478

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000099025

Paralogs (18): ZNF430 (ENSG00000118620), ZNF92 (ENSG00000146757), ZNF66 (ENSG00000160229), ZNF22 (ENSG00000165512), ZNF680 (ENSG00000173041), ZNF114 (ENSG00000178150), ZFP41 (ENSG00000181638), ZNF730 (ENSG00000183850), ZNF479 (ENSG00000185177), ZNF626 (ENSG00000188171), ZNF431 (ENSG00000196705), ZNF257 (ENSG00000197134), ZNF98 (ENSG00000197360), ZNF675 (ENSG00000197372), ZNF273 (ENSG00000198039), ZNF737 (ENSG00000237440), ZNF253 (ENSG00000256771), ZNF723 (ENSG00000268696)

Protein

Protein identifiers

Zinc finger protein 100 — Q8IYN0 (reviewed: Q8IYN0)

All UniProt accessions (4): Q8IYN0, A0A0A0MTN5, M0R071, M0R0Q1

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (5): NP_001338598, NP_001338599, NP_001338600, NP_001338601, NP_775802* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (17 total): zinc finger region 12, sequence variant 2, chain 1, domain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IYN0-F1	67.97	0.14

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 53 (showing top): WEI_MYCN_TARGETS_WITH_E_BOX, chr19p12, DODD_NASOPHARYNGEAL_CARCINOMA_UP, FISCHER_DREAM_TARGETS, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ASH1L_TARGET_GENES, CEBPZ_TARGET_GENES, HMG20B_TARGET_GENES, HSD17B8_TARGET_GENES, NFE2L1_TARGET_GENES, PRKDC_TARGET_GENES, ZNF184_TARGET_GENES, ZNF618_TARGET_GENES, MIR616_5P

GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

270 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF100	ARRDC5	A6NEK1	398
ZNF100	NUDT13	Q86X67	322
ZNF100	SP140L	Q9H930	315
ZNF100	AAMDC	Q9H7C9	306
ZNF100	MIF4GD	A9UHW6	301
ZNF100	ZNF618	Q5T7W0	299
ZNF100	RHOXF2	Q9BQY4	298
ZNF100	FANCD2	Q9BXW9	293
ZNF100	DELE1	Q14154	290
ZNF100	GPR180	Q86V85	288
ZNF100	INO80E	Q8NBZ0	277
ZNF100	HYPK	Q9NX55	270
ZNF100	OR10S1	Q8NGN2	247
ZNF100	PLA1A	Q53H76	245
ZNF100	PRSS38	A1L453	225

IntAct

32 interactions, top by confidence:

A	B	Type	Score
NEUROG3	GXYLT2	psi-mi:“MI:0914”(association)	0.640
POLR2F	POLR3A	psi-mi:“MI:0914”(association)	0.640
KRTAP12-2	ZNF100	psi-mi:“MI:0915”(physical association)	0.560
FGF3	GTPBP10	psi-mi:“MI:0914”(association)	0.530
N	NOP56	psi-mi:“MI:0914”(association)	0.530
N	RBM47	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF316	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ECE1	ZNF100	psi-mi:“MI:0915”(physical association)	0.370
TIMM50	ZNF724	psi-mi:“MI:0914”(association)	0.350
TNFRSF19	NOP56	psi-mi:“MI:0914”(association)	0.350
N	RBM47	psi-mi:“MI:0914”(association)	0.350
RPL27A	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZNF467	ZNF320	psi-mi:“MI:0914”(association)	0.350
LRP3	TMEM131L	psi-mi:“MI:0914”(association)	0.350
ABT1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
FGFBP1	ZNF724	psi-mi:“MI:0914”(association)	0.350
ANOS1	ZNF724	psi-mi:“MI:0914”(association)	0.350
TNFRSF19	PLD2	psi-mi:“MI:0914”(association)	0.350
ZNF653	URB1	psi-mi:“MI:0914”(association)	0.350
TIMM50	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZNF100	KRTAP12-2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (55): ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-RNA), KRTAP12-2 (Two-hybrid), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS), ZNF100 (Affinity Capture-MS)

ESM2 similar proteins: A0A1W2PQL4, A0JPL0, A2RRD8, A6NHJ4, A6NP11, B4DX44, O75346, O95780, P0CB33, P21506, P51508, P52738, Q0D2J5, Q0VGE8, Q12901, Q13360, Q14593, Q15973, Q2M218, Q2M3X9, Q2VY69, Q3SXZ3, Q5HY98, Q5RCJ2, Q5VIY5, Q6J6I6, Q7L2R6, Q86XU0, Q86Y25, Q8IW36, Q8IYN0, Q8IYX0, Q8N782, Q8N883, Q8N9Z0, Q8NDP4, Q95K49, Q969W8, Q96H40, Q96N58

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

124 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	96
Likely benign	17
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

995 predictions. Top by Δscore:

Variant	Effect	Δscore
19:21727985:TATAA:T	acceptor_gain	1.0000
19:21727987:TAA:T	acceptor_gain	1.0000
19:21727990:C:CC	acceptor_gain	1.0000
19:21727986:ATAA:A	acceptor_gain	0.9900
19:21727990:C:A	acceptor_loss	0.9900
19:21727991:T:G	acceptor_loss	0.9900
19:21744980:T:A	donor_gain	0.9900
19:21765710:TG:T	donor_gain	0.9900
19:21767366:T:TA	donor_gain	0.9900
19:21767367:C:A	donor_gain	0.9900
19:21727988:AA:A	acceptor_gain	0.9800
19:21765688:GGTTA:G	donor_loss	0.9800
19:21765689:GTTA:G	donor_loss	0.9800
19:21765690:TTA:T	donor_loss	0.9800
19:21765691:TA:T	donor_loss	0.9800
19:21765692:A:C	donor_loss	0.9800
19:21765693:C:CA	donor_loss	0.9800
19:21767222:C:CT	donor_gain	0.9800
19:21767223:T:TT	donor_gain	0.9800
19:21767280:ATGG:A	donor_gain	0.9800
19:21765787:C:CC	acceptor_gain	0.9700
19:21767252:T:TA	donor_gain	0.9700
19:21767421:TCTCA:T	donor_loss	0.9700
19:21767422:CTCAC:C	donor_loss	0.9700
19:21767423:TCAC:T	donor_loss	0.9700
19:21767424:CAC:C	donor_loss	0.9700
19:21767426:C:CG	donor_loss	0.9700
19:21767461:G:C	donor_gain	0.9700
19:21753437:G:C	donor_gain	0.9600
19:21740813:T:TC	acceptor_gain	0.9500

AlphaMissense

3610 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:21726914:A:C	F466L	0.990
19:21726914:A:T	F466L	0.990
19:21726916:A:G	F466L	0.990
19:21727502:A:C	F270L	0.990
19:21727502:A:T	F270L	0.990
19:21727504:A:G	F270L	0.990
19:21726998:A:C	F438L	0.989
19:21726998:A:T	F438L	0.989
19:21727000:A:G	F438L	0.989
19:21727418:A:C	F298L	0.989
19:21727418:A:T	F298L	0.989
19:21727420:A:G	F298L	0.989
19:21727329:C:G	R328P	0.987
19:21727413:C:G	R300P	0.987
19:21727250:A:C	F354L	0.986
19:21727250:A:T	F354L	0.986
19:21727252:A:G	F354L	0.986
19:21727334:A:C	F326L	0.983
19:21727334:A:T	F326L	0.983
19:21727336:A:G	F326L	0.983
19:21727497:C:G	R272P	0.982
19:21726830:A:C	F494L	0.981
19:21726830:A:T	F494L	0.981
19:21726832:A:G	F494L	0.981
19:21726909:C:G	R468P	0.981
19:21726981:A:G	L444P	0.980
19:21727082:A:C	F410L	0.975
19:21727082:A:T	F410L	0.975
19:21727084:A:G	F410L	0.975
19:21745032:G:C	F44L	0.975

dbSNP variants (sampled 300 via entrez): RS1000032191 (19:21766663 T>C), RS1000069280 (19:21732476 G>C), RS1000093870 (19:21765034 A>G), RS1000238741 (19:21738173 C>G,T), RS1000268404 (19:21766976 A>G), RS1000364763 (19:21749682 C>T), RS1000512811 (19:21723393 T>A), RS1000580823 (19:21728626 C>A,G), RS1000649971 (19:21723276 C>G), RS1000736652 (19:21754391 A>G), RS1000757677 (19:21723650 C>T), RS1000765391 (19:21761812 C>T), RS1000771654 (19:21755321 A>C), RS1000834536 (19:21760609 A>G), RS1000868248 (19:21749276 GTA>G)

Disease associations

OMIM: gene MIM:603982 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST005790_43	Rosacea symptom severity	4.000000e-06
GCST006627_6	Diastolic blood pressure	7.000000e-11
GCST011117_1	Pancreatic cancer	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009180	rosacea severity measurement
EFO:0006336	diastolic blood pressure

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3795247	ZNF100		0.00	0

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
hydroxyhydroquinone	increases expression	1
pinosylvin	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Sunitinib	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Arsenic	increases expression, increases abundance	1
Benzo(a)pyrene	increases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Methyl Methanesulfonate	increases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Tobacco Smoke Pollution	decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer